Dosimetric review of cardiac implantable electronic device patients receiving radiotherapy by Prisciandaro, Joann I. et al.
a Corresponding author: Joann I. Prisciandaro, University of Michigan Hospital and Health Systems, Department 
of Radiation Oncology, 1500 East Medical Center Dr., UH B2 C438, SPC 5010, Ann Arbor, MI 48109, USA; 
phone: (734) 936 4309; fax: (734) 936 7859; email: joannp@med.umich.edu
Dosimetric review of cardiac implantable electronic device 
patients receiving radiotherapy 
Joann I. Prisciandaro,1a Akash Makkar,2,3 Colleen J. Fox,1,4 James A. 
Hayman,1 Laura Horwood,2 Frank Pelosi,2 and Jean M. Moran1
Department of Radiation Oncology,1 University of Michigan, Ann Arbor, MI; Department 
of Internal Medicine,2 University of Michigan, Ann Arbor, MI; Arizona Heart Rhythm 
Center,3 Phoenix, AZ; Department of Radiation Oncology,4 Dartmouth-Hitchcock 
Medical Center, Lebanon, NH
joannp@med.umich.edu
Received 2 July, 2014; accepted 10 October, 2014
A formal communication process was established and evaluated for the manage-
ment of patients with cardiac implantable electronic devices (CIEDs) receiving 
radiation therapy (RT). Methods to estimate dose to the CIED were evaluated 
for their appropriateness in the management of these patients. A retrospective, 
institutional review board (IRB) approved study of 69 patients with CIEDs treated 
with RT between 2005 and 2011 was performed. The treatment sites, techniques, 
and the estimated doses to the CIEDs were analyzed and compared to estimates 
from published peripheral dose (PD) data and three treatment planning systems  
(TPSs) — UMPlan, Eclipse’s AAA and Acuros algorithms. When measurements 
were indicated, radiation doses to the CIEDs ranged from 0.01–5.06 Gy. Total 
peripheral dose estimates based on publications differed from TLD measurements 
by an average of 0.94 Gy (0.05–4.49 Gy) and 0.51 Gy (0–2.74 Gy) for CIEDs within 
2.5 cm and between 2.5 and 10 cm of the treatment field edge, respectively. Total 
peripheral dose estimates based on three TPSs differed from measurements by an 
average of 0.69 Gy (0.02–3.72 Gy) for CIEDs within 2.5 cm of the field edge. Of 
the 69 patients evaluated in this study, only two with defibrillators experienced 
a partial reset of their device during treatment. Based on this study, few CIED-
related events were observed during RT. The only noted correlation with treatment 
parameters for these two events was beam energy, as both patients were treated 
with high-energy photon beams (16 MV). Differences in estimated and measured 
CIED doses were observed when using published PD data and TPS calculations. 
As such, we continue to follow conservative guidelines and measure CIED doses 
when the device is within 10 cm of the field or the estimated dose is greater than 
2 Gy for pacemakers or 1 Gy for defibrillators.
PACS number: 87.55.N-




There has been a steady increase in the number of patients presenting with cardiac implantable 
electronic devices (CIEDs) for radiation therapy (RT), namely implantable cardiac pacemak-
ers (ICPs) and cardioverter defibrillators (ICDs).(1,2) These devices have undergone significant 
technological improvements over the last few decades, resulting in lower power consumption, 
greater reliability, and prolonged generator lifespan.(3) However, the complementary metal 
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oxide semiconductors (CMOS) utilized in their circuits are known to be susceptible to ionizing 
and electromagnetic radiation, which may result in transient or permanent device defects.(4-11) 
Recommendations from CIED manufacturers vary widely. Some CIED manufacturers provide 
total dose and dose rate recommendations, while others state that no safe radiation dosage can 
be specified. As such, radiation oncology facilities have relied on consensus­based management 
guidelines which suggest that the CIED be kept outside the primary radiation field(s).(7,10,11)  
AAPM Task Group 34(10) provided six recommendations for managing patients with pace-
makers, three of which are still relevant today: 1) the ICP should not be irradiated with primary 
radiation; 2) the dose to the ICP should be estimated prior to RT; and 3) if the cumulative dose 
to the ICP is expected to exceed 2 Gy, the ICP should be interrogated prior to RT and weekly 
during treatment. Several of these recommendations are still followed today, even though RT 
delivery techniques have changed. Some have argued that the recommended cumulative dose 
limit may be too conservative and/or that other factors, such as the patient’s device dependency, 
should play a role in the perceived potential risk of RT.(7,11,12) However, for patient safety, most 
guidance documents continue to recommend that the CIED dose be estimated and/or measured 
to determine if treatment planning modifications are necessary and to determine the appropriate 
level of patient monitoring.  
Typically, CIEDs are located at the periphery of the treatment field(s) where clinical dose 
calculation algorithms are less accurate.(13-17) Peripheral dose (PD) is made up of contributions 
from leakage radiation, collimator head scatter, and internal scatter.(15,16,18) The contributions of 
each of these components vary based on the distance from the field edge(15) and the treatment 
technique. Additionally, the dosimetric accuracy of TPSs are known to decrease with distance 
from the treatment field aperture(s).(19,20) Since TPSs are not commissioned for PD calcula-
tions and their accuracy is known to decrease with increasing distance from the field edge,(19) 
published data are often used to estimate PDs.(14-18,21) Regardless of the technique utilized to 
assess dose to CIEDs, the method’s accuracy should be high enough for the determination of 
the potential risk the treatment may pose.(7)  
A retrospective, IRB-approved study for patients with CIEDs treated with RT between 2005 
and 2011 was conducted at the University of Michigan as a collaborative effort between the 
Department of Radiation Oncology and the Cardiac Electrophysiology section.  Based on the 
data collected in this study, a summary of the effects of RT on the function of CIEDs, as well 
as an established communication protocol between Electrophysiology and Radiation Oncology, 
was published.(22) The goal of the current study is to investigate dosimetric parameters for 
CIED patients receiving RT to assess whether a correlation between treatment techniques and 
CIED events can be identified, and to determine if our measurement protocol continues to be 
appropriate and necessary.  
 
II. MATERIALS AND METHODS
Sixty­nine patients with CIEDs (19 ICDs and 50 ICPs) were treated in the Department of 
Radiation Oncology between 2005 and 2011. The cardiac devices were manufactured by 
Biotronik, Boston Scientific, Medtronic, or St. Jude, and patients were treated to a variety of 
sites, including 21 patients treated to multiple sites.(22) Thirty­five patients were treated with 
3D conformal plans which included at least one wedged field, 13 patients were treated with at 
least one intensity­modulated radiation therapy (IMRT) plan (1.8–2.5 Gy/fx), six patients were 
treated with at least one stereotactic body radiation therapy (SBRT) lung plan (8–18 Gy/fx), 
and one patient was treated with two intracranial stereotactic radiosurgery (SRS) plans (single 
16 and 21 Gy treatment). In addition, 36 patients (24 with ICPs and 12 with ICDs) were treated 
with a plan that included at least one high-energy (16 MV) photon beam. A summary of the 
treatment techniques and the number of treatment plans generated is provided in Table 1. All 
clinical treatment plans were developed using an in-house TPS, UMPlan, which is based on 
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principles outlined in Fraass et al.,(23) but modified for improved heterogeneity calculations. 
Patients were treated on one or more of the following linac models: 2100CD, 21-EX, 21-iX, 
or 600CD (Varian Medical Systems, Palo Alto, CA).
The distances from the edge of the radiation field to the CIEDs for this patient cohort ranged 
from 1.5 cm to greater than 40 cm. Five patients (2 with ICPs and 3 with ICDs) with devices 
< 2.5 cm from the treatment field edge were determined to be medically high­risk and did not 
undergo CIED relocation. These patients had their CIEDs monitored daily by Electrophysiology 
while receiving RT. Clinically, the dose to the CIED for each patient was estimated prior to 
the start of treatment using published PD data (Fraass and van de Geijn(14) for photon beams 
and Chow and Grigorov(21) for electron beams). Estimates were biased to the most conserva-
tive dose based on the available field size, distance, and depth data in the publications. If the 
estimated dose to the device was expected to exceed 1 Gy for ICDs(4) or 2 Gy for ICPs,(10) or 
if the device was less than 10 cm from the edge of a treatment field, the dose was measured 
during the first treatment using TLD­100 disks (Thermo Fisher Scientific, Oakwood Village, 
OH). The TLDs were placed under 1.0–2.0 cm of bolus on the CIED generator in the position 
of nearest approach to the treatment fields and were in place for the imaging (when applicable) 
and treatment fields. After irradiation, the TLDs were annealed for 10 min in a 100°C preheated 
oven. The TLD disks were then individually read using a Harshaw model 3500 manual reader 
(Thermo Fisher Scientific). The total dose for the treatment course was estimated based on this 
measurement to enable determination of the appropriate level of oversight.
For the purpose of this study, the CIED dose was also estimated using published PD data 
from Stovall et al.,(15) Stern,(16) and Mutic and Klein(17) for patients whose CIED was less than 
10 cm from any field edge. A reference point was added in the TPS at the location of the CIED 
closest to the field edge. The dose to this point was calculated using three TPSs: 1) the clinical 
treatment planning algorithm, UMPlan; 2) Eclipse version 11.031 with the analytical anisotropic 
algorithm (AAA); and 3) Eclipse version 11.031 with the Acuros algorithm (Varian Medical 
Systems). For the Acuros calculations, the CT calibration curve was extended to include CT 
data for titanium based on the recommendation of Gossman et al.(3) The CIED generator and 
leads were contoured and assigned the material properties of titanium (density of 4.42 g/cm3). 
The high-density artifacts from the CIED generator and leads were segmented and assigned a 
water-equivalent density (1 g/cm3).     
 
III. RESULTS 
For this cohort of 69 patients, dose estimates based on TLD measurements ranged from 
0.9 to 506 cGy and 4 to 169 cGy for ICPs and ICDs, respectively. Figure 1 and Table 2 pres-
ent the estimated and measured doses to the CIEDs for devices which were less than 2.5 cm 
and 2.5–10 cm from the edge of the treatment field, respectively. For this study, the PD 
estimates were based on data published by Fraass and van de Geijn,(14) Stovall et al.,(15) Stern,(16) 
Table 1. A summary of the treatment techniques and plans for the 69 patient cohort. The number of plans listed per 
technique includes the initial treatment plan, replans, and boosts.  
  Number of  Dose/Fraction Total Dose
 Treatment Technique Treatment Plans Range (Gy/fx) Range (Gy)
 Electron(s) 16 2–4 4–50
 3D Conformal 53 1.5–8 4–68.4
 3D Conformal with wedge(s) 53 1.5–8 4–64.8
 IMRT 17 1.8–2.5 26–77.7
 SRS 2 16–21 16–21
 SBRT 9 8–18 40–54
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and Mutic and Klein(17) for photons and Chow and Grigorov(21) for electrons. For distances of 
less than 2.5 cm, the total PD estimates based on published data(14-17) differed from measure-
ments by an average of 0.94 Gy (0.05–4.49 Gy) across the four publications (Fraass and van 
de Geijn(14): 0.89 Gy [0.05–3.19 Gy]; TG34(15): 0.78 Gy [0.25–1.89 Gy]; Stern(16): 0.88 Gy 
[0.36–2.18] ; and Mutic and Klein(17): 1.22 Gy [0.25–4.49Gy]). For distances between 2.5 cm 
and 10 cm, the total PD estimates based on these same publications differed from measurements 
by 0.51 Gy (0–2.74 Gy) — (Fraass and van de Geijn(14): 0.76Gy [0.02–2.26Gy]; TG34(15): 
0.41 Gy [0.01–1.67 Gy]; Stern(16): 0.45 Gy [0.04–2.50 Gy]; and Mutic and Klein(17): 0.45 Gy 
[0–2.74 Gy]).  
Table 3 summarizes the TPS calculated doses to the CIEDs for patients whose device was 
less than 2.5 cm from the field edge based on the TPSs’ algorithms. When compared to the TLD 
measurements, the CIED total dose differed by an average of 0.69 Gy (0.02–3.72 Gy) across 
all three TPSs (UMPlan: 0.54 Gy [0.06–1.61 Gy]; AAA: 0.78 Gy [0.02–3.41 Gy]; Acuros: 
0.73 Gy [0.05–3.72 Gy]).
Of the 69 patients evaluated, only two ICD patients experienced a partial reset of their device, 
which resulted in the loss of the patient’s diagnostic data. Both patients were treated with plans 
that included at least one 16 MV (%dd(10)x = 77.7) photon beam. The ICD for one of these 
patients was < 2.5 cm from the radiation treatment fields.      
 
Fig. 1. Estimated total CIED dose normalized to the prescribed central axis (CAX) dose for all patients and plans where 
the CIED was less than 2.5 cm from the edge of a treatment field. The estimated PDs are based on Fraass and van de 
Geijn,(14) TG34,(15) Stern,(16) and Mutic and Klein,(17) and the estimates for Patient 54 are shown for both 16X and 6X 
treatment plans that were utilized for this patient (16X plan was discontinued after one treatment fraction).  
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Table 2. Estimated vs. measured CIED doses for all patients and plans in which the CIED was between 2.5 and 10 cm 
from the edge of a treatment field (distance between CIED and closest treatment field edge indicated in the column 
labeled “d”).  The estimated doses were based on the publications of Fraass and van de Geijn,(14) TG34,(15) Stern,(16) 
and Mutic and Klein,(17) and Chow and Grigorov,(21) as well as in vivo measurements.
 Plan Parameters Estimated Total Dose
   Total
   Prescription
   Dose (Gy) E (MV     TLD
 Pt. Treatment (Dose/fx or Treatment  d Dose (Gy) Result
 # Site [Gy/fx]) MeV) Technique Device  (cm) Fraass/TG34/Stern/Mutic  (Gy)
 4 Upper extremity 8 (8) 6X 3D with wedge ICD 4 0.43/ 0.40/ 0.21/ 0.09 0.49
 8 Esophagus 50 (2) 6X 3D ICP 5 2.75/ 2.00/ 1.28/ 0.58 0.58
 11 Esophagus 30 (1.5) 16X 3D ICD 3 1.59/ 0.30/ 1.46/ 0.33 0.72
  Esophagus 30 (1.5) 16X 3D ICD 4.5 1.59/ 0.30/ 0.58/ 0.33 0.54
  Esophagus 15 (1.5) 16X 3D with wedge ICD 5 0.80/ 0.15/ 0.22/ 0.16 ---
 14 Breast and thorax 39 (3) 6X 3D with wedge ICP 4 1.01/ 0.86/ 0.69/ 0.42 0.73
 16 Head and neck 60 (2) 6X IMRT ICP 5 3.24/ 0.66/ 1.33/ 0.69 1.02
 17 Head and neck 50 (2.5) 6X 3D with wedge ICP 5 2.70/ 1.00/ 0.74/ 0.54 0.44
 20 Breast and thorax 60 (2)
 6X, 9e,
    12e 3D ICP 9.9 0.96/ 0.60/ 0.84/ 0.60 0.75
 27 Breast and thorax 37.5 (2.5) 6X 3D with wedge ICP 5 0.56/ 0.75/ 0.56/ 0.38 0.36
 31 Esophagus 50 (2) 16X 3D ICP 8 0.95/ 0.25/ 0.37/ 0.50 0.79
 33 Head and neck 70 (2)  6X IMRT ICP 5 3.85/ 2.66/ 1.68/ 0.81 2.84
 35 Breast and thorax 60 (2) 6X 3D ICP 4 3.30/ 2.88/ 1.68/ 0.71 3.45
 36 Head and neck 16 (2) 16X 3D with wedge ICP 3.5 2.50/ 0.51/ 0.69/ 0.54 0.89
 38 Breast and thorax 30 (3) 6X 3D ICP 5.5 1.62/ 0.39/ 0.55/ 0.31 0.46
 40 Breast and thorax 45 (9) 6X,16X SBRT ICP 8 0.50/ 0.18/ 0.15/ 0.32 0.19
 41 Head and neck 24 (2) 6X 3D ICP 9.6 0.13/ 0.12/ 0.12/ 0.19 0.84
 42 Breast and thorax 50 (10) 6X,16X SBRT ICP 7 0.88/ 0.20/ 0.12/ 0.50 0.50
 44 Breast and thorax 50 (10) 6X SBRT ICP 3.5 0.75/ 0.53/ 1.58/ 0.54 ­­­
  Breast and thorax 50 (10) 6X SBRT ICP 10 0.75/ 0.25/ 0.28/ 0.40 ­­­
 45 Head and neck 70 (2) 6X IMRT ICD 3 3.50/ 3.36/ 4.19/ 0.78 1.69
 47 Upper extremity 50.4 (1.8) 6X 3D ICD 9.8 1.12/ 0.60/ 0.99/ 0.54 0.70
 50 Breast and thorax 24 (2) 6X 3D with wedge ICP 7 0.86/ 0.26/ 0.22/ 0.24 0.33
 55 Head and neck 4 (2) 6X 3D with wedge ICP 10 0.06/ 0.04/ 0.05/ 0.04 0.09
 57 Breast and thorax 50 (2) 16X 3D with wedge ICP 2.5 2.50/ 0.51/ 1.70/ 0.51 1.58
  Breast and thorax 70 (2) 6X IMRT ICP 10 0.39/ 0.34/ 0.42/ 0.56 ­­­
 61 Head and neck 6 (2) 6X 3D with wedge ICP 4.5 0.18/ 0.16/ 0.10/ 0.06 0.57
 64 Esophagus 50.4 (1.8) 16X 3D with wedge ICP 6 1.26/ 0.50/ 0.71/ 0.51 0.86
 68 Spine 30 (3) 16X 3D ICP 10 0.60/ 0.12/ 0.11/ 0.21 0.35
  Spine 20 (4) 6X 3D ICP 6 0.30/ 0.22/ 0.32/ 0.20 0.12
   Estimated
  Plan Parameters Total Dose      
   Total
   Prescription
   Dose (Gy) E (MV     TLD
 Pt. Treatment (Dose/fx or Treatment  d Dose (Gy) Result
 # Site [Gy/fx]) MeV) Technique Device  (cm) Chow  (Gy)
56 Head and neck 50 (2.5) 6e Electron ICD 10 0.2 ---
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IV. DISCUSSION
This study evaluated patients treated with modern RT techniques for which there is limited 
information available regarding the sensitivity of these devices to radiation. Several studies(8,24) 
suggest a small risk of oversensing to CIEDs from CT irradiation which may result in inappropri-
ate inhibition of pacing output for ICPs, with the additional complication of possibly triggering 
unneeded tachyarrhythmia therapy in ICDs.(11) These effects were transient and only observed 
during direct irradiation of the CIED generator.(8,24) As such, we have instituted a preferred 
workflow of assessing the patient’s device dependency prior to their CT simulation, especially 
for patients who will receive a dynamic CT scan (e.g., 4D CT) which involves multiple scans 
of the same region at different time points.  For device-dependent patients, it is important to 
determine if Electrophysiology should be on-set during CT simulations.
Our workflow includes the medical physicist consulting with the dosimetrist to ensure that 
planning choices minimize risk to the device by avoiding high-energy photon beams (> 10 MV) 
and physical wedges, unless their absence would significantly compromise the dose distribution. 
High-energy photons (> 10 MV) are nominally avoided because of the increased probability that 
neutrons will be produced when the photons interact with the atomic nuclei of material they are 
penetrating. Several studies have suggested that neutrons may cause upsets in the memory or 
logic circuits of CIEDs.(24,25) Physical wedges are also avoided to minimize the enhancement 
of dose due to scatter radiation. Where a wedged dose distribution is desired, dynamic wedges, 
multiple field segments, or IMRT should be considered. If a patient’s CIED is less than 10 cm 
from the target, the dose to the CIED is estimated prior to the start of treatment via calculation 
and then with an in vivo measurement on the first day of treatment. We follow the checklist in 
Fig. 2, with the treatment team determining the best approach.  
Care must be taken when selecting the appropriate dosimeter to use for these measurements. 
Thermoluminescent dosimeters have been used widely in clinics for in vivo measurements; 
however, their response may vary based on photon energy and dosimeter model. For instance, 
Table 3. Comparison of the estimated total CIED dose based on measurements as compared to point doses calculated 
using three TPS (UMPlan, Eclipse’s AAA and Acuros), where “d” represents the distance between CIED and closest 
treatment field edge.
  Estimated
  Total Dose  Estimated Total Point Dose
 Plan Parameters to CIED to the CIED
   Delivered     TLD Grid  Eclipse- Eclipse-
 Pt. Treatment Dose  E Treatment  d Result Size UMPlan AAA Acruos
 # Site (Gy) (MV) Technique Device  (cm)   (Gy) (mm)  (Gy)   (Gy) (Gy)
 2 Breast &   3D w/
  Thorax 
45 6x/16x  wedges ICD 1 N/A 3.0 1.79 1.07 2.90
 61 Head &
  Neck 54 6x IMRT ICP 1.5 5.13 3.0 3.52 1.72 1.41
 4 Spine 8 6x/16x
 3D no
     wedges ICD 2 0.65 5.0 0.51 0.38 0.70
 48 Breast &   3D no
  Thorax 
30 6x/16x wedges ICD 2 0.63 3.0 0.56 0.13 0.52
 58 Breast &
  Thorax 
50 6x/16x SBRT ICP 2 0.75 3.0 1.81 0.54 0.57
 54 Esophagus 1.8 16x
  3D w/
     wedges 
ICD
 2.3 1.36 3.0 1.30 1.34 1.25
     
48.6 6x
  3D w/
     wedges  2.3 1.59 3.0 1.92 1.87 1.83
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TLD-100 dosimeters have been shown to be more accurate for photon energies of ≤ 10 MV, 
because they overrespond to thermal neutrons.(26) On the other hand, the TLD-700 dosim-
eter has been reported to be insensitive to neutrons, but is not as widely used in clinic. Chan 
et al.(27) reported a change in sensitivity of 3% (1%–11%) for the TLD-700, a decrease of 10% 
(5%–21%) for OSLDs, and an increase of 16% (11%–19%) for skin QED diodes for distances 
up to 15 cm from edge of the treatment field.  
While it is convenient to obtain PD estimates using TPSs, this approach is significantly 
limited due to inaccuracies in the PD region. Treatment planning systems are not normally 
commissioned for out­of­field calculations, and the accuracy of calculations are known to 
decrease with increasing distance from the field edge.(19,20) For Eclipse’s AAA algorithm version 
8.6 (Varian Medical Systems), Howell et al.(19) observed that PDs were underestimated by the 
TPS by an average of 40% over a range of 3.75 to 11.25 cm from the field edge, and upwards 
of 55% at a distance of 11.25 cm from the field edge.  Similarly, Huang et al.(20) evaluated 
PDs for IMRT treatment plans generated using Pinnacle version 9.0.and reported they were 
underestimated by the TPS by an average of 50%. At distances close to the field edge (3–4 cm), 
errors in excess of 30% were observed, and at large distances from the treatment field, errors 
approached 100%.(20)  
The PD estimates were evaluated by comparing TLD measurements performed on the first 
treatment day for a given plan with 1) dose estimates based on published PD data, and 2) dose 
estimates based on TPS calculations. For distances of less than 2.5 cm, the total PD estimates 
based on published data(14-17) differed from in vivo measurements by an average of 0.69 Gy 
using data from four publications. For distances between 2.5 cm and 10 cm, the total PD 
1. Simulation Check
a. Patient evaluated or scheduled for evaluation with Electrophysiology to verify device dependency.
b. Verify that a CIED alert has been added to the patient’s record.
c. Estimate the distance (cm) from the device to the approximate region of interest. 
d. Verify if patient is scheduled for a 4D simulation.  If so, determine if the device will be irradiated with 
direct beam during the 4D simulation.  If the CIED may be in direct beam and the patient is device 
dependent (or status unknown), contact Electrophysiology.
e. Document the device make, model, and serial number.
2. Planning check
a. Verify that only 6X photons were used and physical wedges were avoided.
b. Estimate the distance (cm) from the device to the closest edge of the treatment field.
c. Estimate the dose/fraction (cGy/fraction) and total dose (cGy) to the device.
d. Verify the patient’s device dependency.  
e. Is the edge of the treatment field > 10 cm from the CIED and/or the dose < 2 Gy (ICP) or < 1Gy 
(ICD)?  If yes, no further action required.  Update patient’s record to indicate in vivo dosimetry not 
required on Day One.
f. Is the edge of the treatment field < 10 cm and/or estimated total dose ≥ 2 Gy (ICP) or ≥ 1 Gy (ICD)?  If 
yes, update patient’s record and add a patient alert to page physics to perform in vivo dosimetry on Day 
One. 
3. First day of treatment (if patient alert added)
a. Place in vivo dosimeter on CIED under bolus.
b. Verify imaging fields do not irradiate CIED.
c. Estimate dose/fraction (cGy/fraction) and total dose (cGy) to the device based on dosimeter readings.
d. Summarize the in vivo results.
e. If the estimated total dose to the CIED is greater than departmental tolerance (2 Gy for ICPs and 1 Gy 
ICDs) notify attending and Electrophysiology to determine cardiac monitoring strategy.
Fig. 2. The Radiation Oncology checklist that is completed for CIED patients presenting for RT treatments.                            
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 estimates based on these same publications differed from in vivo measurements by an average of 
0.51 Gy. These differences may be attributed to uncertainties related to the positioning of the 
TLD, exclusion of the imaging dose in prediction, limited field sizes, energies, and distances 
in the published PD data, and differences in the design of the collimator head between the 
machines in which the published measurements were acquired as compared to the treating 
linacs. For instance, Fraass and van de Geijn(14) and Stovall et al.(15) performed measurements 
on teletherapy units and several different linac models prior to the availability of MLCs. Since 
PD is due to contributions from internal scatter, collimator scatter, and leakage, the presence of 
an MLC will affect the contribution from collimator scatter. Based on the works of Mutic and 
Klein(17) and Stern,(16) the presence of a tertiary MLC was shown to reduce PDs. The Mutic 
study included measurements at 6 and 18 MV for field sizes ranging from 10 × 10 cm2 to 25 × 
25 cm2, whereas the Stern study included measurements for 10 × 10 cm2 and 26 × 26 cm2, 
requiring one to interpolate between these data points for an approximate PD estimate.  
Table 3 summarizes the calculated doses to the CIEDs for patients whose device was less 
than 2.5 cm from the treatment field edge using three treatment planning algorithms. When 
compared to the reported TLD measurements, the dose to the CIED differed by an average of 
0.69 Gy across all three TPSs. These differences may be attributed to uncertainties related to 
the positioning of the TLD, as well as inaccuracies in the TPS algorithm.  
Based on current department monitoring guidelines for CIED patients (2 Gy for ICP patients 
and 1 Gy for ICD patients), the observed difference in the estimated total CIED dose would 
have resulted in a recommended change in patient monitoring in 12 of 69 patients based on 
published PD data and 1 of 6 patients based on TPS calculations. With a 17% chance of inad-
vertently identifying patients in an inappropriate risk category, we continue to follow conser-
vative guidelines and measure CIED doses when the device is within 10 cm of the field or the 
estimated dose is greater than 2 Gy for pacemakers or 1 Gy for defibrillators.
As presented previously,(22) of the 69 patients evaluated in this study, only two ICD patients 
experienced a partial reset of their device during their treatment. The estimated total dose to the 
ICDs for both patients was less than 1 Gy. One of the patient’s CIED was within 2.5 cm of the 
edge of the treatment fields (lung), while the second patient’s CIED was > 10 cm for the region 
of interest (pelvis). While Mouton et al.(12) has suggested a dose rate effect for ICPs, in their 
study, the ICPs were only irradiated with direct, high-energy photons, and dose rate and total 
accumulated dose were not tested independently.  What may be a more plausible cause for the 
observed partial resets in our patient cohort was that both patients were treated with high-energy 
(16 MV) photon beams. As indicated earlier, studies have suggested that neutrons may cause 
upsets in the memory or logic circuits of CIEDs.(24,25) Once the partial resets were identified, 
the treatment plans for both patients were modified and only low­energy photon beams (6 MV) 
were utilized. Both patients completed their course of RT without further incident. Based on 
our experience, we have limited beam energies to less than 10 MV for patients with CIEDs.
 
V. CONCLUSIONS
We have developed a standard management plan for CIED patients presenting for RT. We base 
the degree of surveillance on factors such as distance between the device and treatment site, 
estimated dose to the device, and patient’s device dependency. Few CIED-related events were 
observed during RT for these patients. The only noted correlation with treatment parameters 
for these events was beam energy. As such, we modified our management strategy to limit the 
beam energy used for treating CIED patients.  
Differences in estimated and measured CIED doses were observed when using published PD 
data and TPS calculations. These differences would have resulted in a recommended change in 
patient monitoring in 17% of patients based on both published PD data and TPS calculations. 
262  Prisciandaro et al.: Assessment of RT patients with CIEDs   262
Journal of Applied Clinical Medical Physics, Vol. 16, No. 1, 2015
Due to inaccuracies in the calculated dose outside the field edge, we manage the uncertainties 
in dose estimates by following a conservative guideline and measure when the device is within 
10 cm of the field or is estimated to receive 2 Gy (ICPs) or 1 Gy (ICDs). Regardless of the 
technique utilized to estimate PD to the CIED, the accuracy of the technique should be high 
enough to determine the potential risk RT may pose on the patient.(7)  
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